Zacks Research Upgrades Nautilus Biotechnology (NASDAQ:NAUT) to Hold

Posted by Brenda Bartman on Oct 2nd, 2026

Nautilus Biotechnology (NASDAQ:NAUT – Get Free Report) was upgraded by investment analysts at Zacks Research to a “hold” rating in a research note issued to investors on Wednesday, Zacks reports.

Other research analysts have also issued reports about the company. Weiss Ratings lowered Nautilus Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, August 5th. Leerink Partners began coverage on Nautilus Biotechnology in a report on Wednesday, September 9th. They issued an “outperform” rating and a $4.00 price objective on the stock. Finally, Roth Capital assumed coverage on Nautilus Biotechnology in a research note on Tuesday. They set a “buy” rating and a $3.50 target price on the stock. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $3.83.

Check Out Our Latest Research Report on Nautilus Biotechnology

Nautilus Biotechnology Stock Up 10.6%

NASDAQ:NAUT opened at $1.57 on Wednesday. Nautilus Biotechnology has a 52 week low of $0.82 and a 52 week high of $4.31. The stock’s fifty day moving average is $1.01 and its two-hundred day moving average is $2.01. The company has a market capitalization of $199.78 million, a P/E ratio of -3.49 and a beta of 0.73.

Nautilus Biotechnology (NASDAQ:NAUT – Get Free Report) last posted its quarterly earnings data on Monday, July 27th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03. The company had revenue of $0.19 million for the quarter, compared to analysts’ expectations of $0.10 million. Sell-side analysts anticipate that Nautilus Biotechnology will post -0.52 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Nautilus Biotechnology

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC lifted its position in shares of Nautilus Biotechnology by 2.2% during the 1st quarter. Renaissance Technologies LLC now owns 265,700 shares of the company’s stock worth $1,031,000 after purchasing an additional 5,800 shares during the last quarter. CTC Alternative Strategies Ltd. acquired a new position in shares of Nautilus Biotechnology during the first quarter worth $48,000. TD Waterhouse Canada Inc. increased its holdings in Nautilus Biotechnology by 1,500.0% in the second quarter. TD Waterhouse Canada Inc. now owns 16,000 shares of the company’s stock valued at $29,000 after buying an additional 15,000 shares during the last quarter. Public Employees Retirement System of Ohio purchased a new position in Nautilus Biotechnology in the first quarter valued at $75,000. Finally, Callan Family Office LLC acquired a new stake in Nautilus Biotechnology in the second quarter valued at $49,000. Hedge funds and other institutional investors own 50.71% of the company’s stock.

About Nautilus Biotechnology

(Get Free Report)

Nautilus Biotechnology, Inc is a life sciences technology company developing tools for large-scale protein analysis. Its goal is to help researchers study the proteome—the complete set of proteins produced by a biological system—with greater sensitivity, accuracy and throughput than conventional methods.

The company’s core offering is the Nautilus Protein Analysis Platform, an integrated system that combines specialized instrumentation, consumables and software. The platform is designed to identify and quantify large numbers of proteins from biological samples and may support applications in drug discovery, biotechnology research, academic studies and the development of precision medicine.

Nautilus Biotechnology was founded in 2016 and is headquartered in Seattle, Washington.